Facebook
Twitter
LinkedIn
ForwardOMA 2023 Spring Summit: The Silent Epidemic: An Overview of Non-Alcoholic Fatty Liver Disease (On Demand)
This session will focus on the management of non-alcoholic fatty liver disease (NAFLD) with a particular emphasis on the role of GLP-1 agonists and SGLT-2 inhibitors in treating this condition. The presentation will also review the epidemiology of non-alcoholic fatty liver disease and the initial steps in the evaluation and risk stratification of NAFLD patients presenting in a primary care setting.
CME/CE Expiration Date: 4/23/26
*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
Nader Dbouk, MD
The Obesity Medicine Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the commensurate amount with the extent of their participation in the activity.